TrialNet: Diabetes Type 1 Prevention

TrialNet：1 型糖尿病预防

• 批准号: 9066681
• 负责人: PETER A GOTTLIEB
• 金额: $ 58.72万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9066681
• 关键词: Ancillary Study; Autoimmune Diseases; Autoimmune Process; B-Lymphocytes; Biological Markers; Blood Glucose; C-Peptide; Clinical; Clinical Research; Conduct Clinical Trials; Development; Diabetes Mellitus; Dietary Intervention; Disease; Disease Progression; Enrollment; Functional disorder; Future; Goals; Health; Healthcare Systems; Human; Immune; Immune Tolerance; Immunologics; Immunotherapy; Insulin-Dependent Diabetes Mellitus; Intervention; Knowledge; Metabolic; Participant; Pathogenesis; Physicians; Populations at Risk; Prevention; Productivity; Protocols documentation; Recruitment Activity; Scientist; Study Subject; T-Lymphocyte; United States; Work; cost; human subject; impaired glucose tolerance; improved; monocyte; next generation; prevent

DESCRIPTION (provided by applicant): Multiple treatments that can change the course of type 1 diabetes have been identified over the last several years through the efforts of TrialNet, the Immune Tolerance Network and others. Although these immune therapies can stop disease progression in those with elevated blood sugars, the effect has proven to be transient in most study subjects. The ongoing effort of Type 1 Diabetes TrialNet, its Clinical Centers and affiliates is to continue to develop better therapies to prevent and reverse type 1 diabetes in human subjects. The Barbara Davis Center and its affiliate network has been a central contributor to these efforts from the beginning of DPT-1 through TrialNet and we hope with renewal of our Clinical Center to be able to continue to push towards these aims as well as develop the next generation of physician-scientists who can build on the work accomplished so far. Our aim is not only to conduct excellent clinical research which can answer the main study questions being examined: most often metabolic - development of impaired glucose tolerance, overt diabetes or reduced C-peptide, but also to develop immune biomarkers which can help us better understand the pathogenesis of disease progression and identify secondary markers of responder groups that allow us to better tailor our therapies to achieve successful prevention of T1D.

描述（由申请人提供）：在过去几年中，通过 TrialNet、免疫耐受网络和其他机构的努力，已经确定了可以改变 1 型糖尿病病程的多种治疗方法。尽管这些免疫疗法可以阻止血糖升高的疾病进展，但事实证明这种效果在大多数研究对象中是短暂的。 1 型糖尿病 TrialNet、其临床中心和附属机构的持续努力 目标是继续开发更好的疗法来预防和逆转人类 1 型糖尿病。从 DPT-1 开始到 TrialNet，芭芭拉·戴维斯中心及其附属网络一直是这些努力的核心贡献者，我们希望通过更新我们的临床中心，能够继续推动实现这些目标，并培养下一代医师科学家，他们可以在迄今为止所完成的工作的基础上再接再厉。我们的目标不仅是进行出色的临床研究来回答正在检查的主要研究问题：最常见的是代谢 - 糖耐量受损、明显的糖尿病或 C 肽减少的发展，而且还开发免疫生物标志物，帮助我们更好地了解疾病进展的发病机制，并确定反应者群体的次要标志物，使我们能够更好地调整我们的治疗方案，以成功预防 T1D。